Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pledges 10% Reduction In NDA Review Time As Part Of “Strategic Plan”

Executive Summary

FDA plans to deliver a two-month reduction in review times for standard new molecular entity NDA filings as one "benchmark" for the agency's "strategic plan.
Advertisement

Related Content

NDA Review Times Are Down 55 Days, FDA Says
NDA Review Times Are Down 55 Days, FDA Says
Hemispherx Ampligen NDA Plans Could Pose Challenge For FDA
Hemispherx Ampligen NDA Plans Could Pose Challenge For FDA
FDA Strategic Plan: Milestones Will Be Unveiled In June
FDA Strategic Plan: Milestones Will Be Unveiled In June
Rite Aid Makes Drugstore.com Its Online Pharmacy With $8 Mil. Investment
Covance, Parexel Will Pursue Smaller Acquisitions Following Merger Failure
Advertisement
UsernamePublicRestriction

Register

PS042039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel